The Prescription Drug User Fee Act: Much More Than User Fees.
Level 5 - mechanism / opinion, no new human data
Qualitative policy and legislative document review (by design analogy, not clinical CEBM)
PubMed 35149663 · doi:10.1097/MLR.0000000000001692
What was done
The authors reviewed the full texts of all historical Prescription Drug User Fee Act (PDUFA) reauthorization bills over the law's 29-year history, as well as submitted public comments and meeting minutes for the 2022 reauthorization cycle. They identified provisions altering Food and Drug Administration (FDA) regulatory authority and processes.
What was found
The abstract reports qualitative policy findings and contains no numerical data. PDUFA reauthorizations have introduced policy changes that lowered evidentiary standards for drug approval, created accelerated approval pathways, increased industry involvement in FDA decision-making, altered rules for industry information dissemination to providers, and affected generic market entry. The 2022 reauthorization negotiations highlighted industry priorities around utilizing real-world evidence, achieving regulatory certainty, and increasing FDA-industry communication during application reviews.
Why it matters
This review highlights how routine funding reauthorizations can systematically reshape drug regulatory standards and deepen agency dependency on industry negotiations.
Limits
The abstract provides no sample sizes, counts of reviewed documents, or structured coding metrics. Findings are qualitative, descriptive, and specific to United States pharmaceutical regulation.
Cited by
- supports The majority of the FDA's drug approval review division budget is funded by pharmaceutical company user fees rather than taxpayers.